Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 4/20 | 0.31 |
| ▸ | Q9HBH1 | 1/20 | 0.30 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089363 | 0.98 | SLC15A2 (0.44) | SLC15A2MMP1NMT2NMT1OPRK1 | |
| SCHEMBL5598844 | 0.90 | SLC15A2 (0.52) | SLC15A2OPRK1CALCRL | |
| SCHEMBL2243005 | 0.90 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL2815083 | 0.90 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL4589980 | 0.88 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL4587124 | 0.88 | SLC15A2 (0.54) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL2247601 | 0.87 | SLC15A2 (0.42) | SLC15A2MMP1GHSRPDF | |
| SCHEMBL9080875 | 0.86 | GHSR (0.41) | OPRK1GHSR | |
| SCHEMBL9616919 | 0.86 | SLC15A2 (0.52) | SLC15A2MMP1NMT2NMT1CALCRL | |
| SCHEMBL5969804 | 0.85 | SLC15A2 (0.41) | SLC15A2MMP1OPRK1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | PROCYTE CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7179789-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| WO-2006023465-A1 | POLYETHYLENE GLYCOL-PEPTIDE COPPER COMPLEXES AND COMPOSITIONS AND METHODS RELATED THERETO | PROCYTE CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005097061-A1 | ENCAPSULATED PEPTIDE COPPER COMPLEXES AND COMPOSITIONS AND METHODS RELATED THERETO | PROCYTE CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| US-6927206-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| US-6927205-B2 | Compositions and methods for treatment of psoriasis | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| EP-0765152-B1 | STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORP (US) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | CUTA, AOC1, RCN1 | SLC15A2 2091/4885MMP1 31/4885NMT2 3869/4885 |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | SLC15A2 1553/4885MMP1 2394/4885NMT2 1991/4885 |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | CUTA, TYR, EYA3 | SLC15A2 2514/4885MMP1 586/4885NMT2 2644/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | SLC15A2 3106/4885MMP1 964/4885NMT2 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.